Athenex drops after FDA restates need for new trial for breast cancer treatment

Athenex

06/07/2021 17:19

** Shares of drugmaker  ATNX.O  fall 6.7% to $4.25
    ** Co provides update from meeting with U.S. FDA, held in 
Q2 of this year, to discuss concerns raised for its treatment
for metastatic breast cancer  urn:newsml:reuters.com:*:nGNX4yHqF2
    ** Co says FDA has agreed that a well-designed and
well-conducted trial may adequately address the deficiencies
raised by the health regulator earlier
    ** In March, FDA declined to approve the treatment, citing
safety risk and asked ATNX to conduct new clinical trial in a
patient population with metastatic breast cancer representative
of U.S. population  urn:newsml:reuters.com:*:nL3N2KZ35Q
    ** ATNX is evaluating optimal design for new clinical study,
which it intends to present to FDA in Q4 of 2021
    ** Stock down about 62% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))